(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual revenue growth rate of 50.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Casi Pharmaceuticals's revenue in 2024 is $42,264,000.On average, 1 Wall Street analysts forecast CASI's revenue for 2024 to be $791,987,960, with the lowest CASI revenue forecast at $791,987,960, and the highest CASI revenue forecast at $791,987,960. On average, 1 Wall Street analysts forecast CASI's revenue for 2025 to be $1,476,950,520, with the lowest CASI revenue forecast at $1,476,950,520, and the highest CASI revenue forecast at $1,476,950,520.
In 2026, CASI is forecast to generate $1,878,161,988 in revenue, with the lowest revenue forecast at $1,878,161,988 and the highest revenue forecast at $1,878,161,988.